Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
Market Cap:73.5M; Shares Outstanding:9.2M; Short Interest: 15.46%; Q3 2019(9/30/19): Cash 17.8M. Loss 0.7M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 29，no change
Shares hold: 1825.1k shares. no change
shares% hold: 10.6%，no change